TREg Activation in the Treatment of the PELADE (Alopecia Areata) (TreatPelade)
TREg Activation in the Treatment of the PELADE (Alopecia Areata). Double Blind Randomized Placebo Controlled Comparative Study Using Low Doses of IL2
Sponsor: Centre Hospitalier Universitaire de Nice
This PHASE3 trial investigates Alopecia Areata and is currently completed. Centre Hospitalier Universitaire de Nice leads this study, which shows 7 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2018 — Jan 2020 [monthly]
Active Not Recruiting PHASE3
▶ Show 2 earlier versions
-
Jan 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Jan 2018 [monthly]
Recruiting PHASE3
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Hospitalier Universitaire de Nice
For direct contact, visit the study record on ClinicalTrials.gov .